Belgian Diversified Financial Stock News

Why Syensqo’s portfolio review matters for shareholders Syensqo (ENXTBR:SYENS) has kicked off a review of its Performance & Care segment, signalling a possible reshaping of the business to concentrate more on specialty materials and advanced technologies. For you as an investor, the key question is how a potential change in scope for Performance & Care, which generated €2,000 million in net sales and €358 million in underlying EBITDA in 2025, could influence the profile of the remaining...

Solvay (ENXTBR:SOLB) has drawn fresh attention after signing a Letter of Intent with Viridis Mining and Minerals to source rare earth feedstocks from Brazil for its La Rochelle processing plant in France. See our latest analysis for Solvay. The rare earth agreement comes as Solvay’s share price shows mixed momentum, with a 1-day share price return of 2.24% and 7-day share price return of 1.15%, offset by a 30-day share price return that is down 5.16%. At the same time, the 3-year total...

Why Umicore stock is drawing attention now Umicore (ENXTBR:UMI) has caught investor attention after a strong recent share price move, with the stock up about 47% over the past month and roughly 49% over the past 3 months. See our latest analysis for Umicore. That recent surge sits within a mixed picture, with a 36.31% year to date share price return and a very strong 1 year total shareholder return of 166.21%, but a 44.30% decline in total shareholder return over 5 years, which hints at...

UCB (ENXTBR:UCB) is back in focus after The Lancet published full Phase 3 PHOENYCS GO results for dapirolizumab pegol in moderate to severe systemic lupus erythematosus, highlighting statistically significant disease activity improvements and a favorable safety profile. See our latest analysis for UCB. The recent lupus data arrive after a strong run in UCB’s stock, with a 1 month share price return of 9.95% and a year to date share price return of 8.54%. The 1 year total shareholder return of...

Retail Estates earnings put recent share performance in context Retail Estates (ENXTBR:RET) recently reported full year results to March 31, 2026, with sales of €146.12 million and net income of €122.95 million, drawing fresh attention to the stock after the announcement. See our latest analysis for Retail Estates. At a share price of €71.0, the stock has been relatively steady in the very short term. However, the 30 day share price return of 4.57% and year to date share price return of...

Tessenderlo Group NV ( EBR:TESB ) stock is about to trade ex-dividend in three days. The ex-dividend date is two...

As European markets experience a positive momentum with the STOXX Europe 600 Index rising by 3.00%, optimism is fueled by hopes of easing geopolitical tensions in the Middle East. However, economic growth forecasts have been trimmed due to energy shocks and volatile trade environments, creating a landscape where identifying stocks potentially undervalued becomes crucial for investors seeking opportunities amidst uncertainty. In such conditions, a good stock might be one that demonstrates...

ageas SA/NV ( EBR:AGS ) is about to trade ex-dividend in the next four days. The ex-dividend date is two business days...

Payton Planar Magnetics (ENXTBR:PAY) has just posted Q1 2026 revenue of US$10.65 million with basic EPS of US$0.08. This sets the tone for how investors will read the latest numbers against a year in which trailing twelve month EPS was US$0.55 on revenue of US$46.83 million. Over recent quarters, revenue has ranged between US$9.61 million and US$13.23 million while quarterly basic EPS has moved between US$0.08 and US$0.20. This gives investors a clear view of how top line and per share...

Cofinimmo (ENXTBR:COFB) has drawn investor attention after its recent share performance, with the stock down about 2% over the past month and about 9% over the past 3 months. See our latest analysis for Cofinimmo. Looking beyond the recent pullback, Cofinimmo’s share price at €83.75 sits above its level at the start of the year, with a year to date share price return of 4.49% and a 1 year total shareholder return of 15.30%. This suggests that momentum has cooled in the short term but remains...

Wondering if Umicore at €25.62 is offering genuine value or just catching your eye after a strong run? This article breaks down what the current price might be implying. The stock has recently returned 4.9% over 7 days, 50.2% over 30 days, 37.8% year to date, and 178.3% over 1 year, which naturally raises questions about how much of the story is already in the price. Recent coverage has focused on Umicore's position in materials and related technologies, with investors paying close attention...

If you are wondering whether Ackermans & Van Haaren at €274.80 is still offering value or if most of the opportunity has already been priced in, this article walks through what the current valuation is really indicating. The stock is up 18.1% year to date and 22.1% over the last year, with a 3 year return of 84.0% and a 5 year return of 118.3%. However, it has slipped 1.0% over the last week and sits only 0.6% higher over the past month. Recent coverage has focused on Ackermans & Van Haaren...

As European markets experience a notable upswing, with the STOXX Europe 600 Index climbing by 3% amid hopes for geopolitical de-escalation, investors are increasingly seeking stable returns in an environment marked by adjusted growth forecasts and persistent inflation concerns. In such a climate, dividend stocks can offer an attractive option for generating income, as they provide regular payouts that can help offset market volatility and economic uncertainties.

Syensqo (ENXTBR:SYENS) has launched a review of its Performance & Care segment, aiming to sharpen its focus on specialty materials and advanced technologies, a shift that could reshape the company’s portfolio and long term priorities. See our latest analysis for Syensqo. At a share price of €67.4, Syensqo’s 21.22% 1 month share price return contrasts with a 13.94% decline over the past 90 days and a modest 3.49% 1 year total shareholder return. This suggests that short term momentum has...

Recent share performance and what it might signal argenx (ENXTBR:ARGX) has drawn investor attention after recent share price moves, with the stock up 0.7% over the past day, 4.5% over the past week and about 6% over the past month. Those gains contrast with a slight decline of about 0.5% over the past 3 months and a year to date return down roughly 2.5%, while the 1 year total return stands at about 35.6%. See our latest analysis for argenx. Recent gains in the share price, including the 1...

Interim dividend decision and what it means for KBC Ancora shareholders KBC Ancora (ENXTBR:KBCA) has drawn fresh attention after its Board of Directors approved an interim dividend of €4.32 gross per share, payable on 4 June 2026, with no final dividend planned for the period. See our latest analysis for KBC Ancora. The interim dividend decision follows a steady run in the stock, with a 30 day share price return of 3.26% and a year to date share price return of 5.18%. This sits alongside a 1...

EVS Broadcast Equipment SA ( EBR:EVS ) stock is about to trade ex-dividend in 3 days. The ex-dividend date is commonly...

In the first quarter of 2026, Syensqo reported sales of €1,461 million, with net income improving to €62 million from a small loss a year earlier, and basic earnings per share rising to €0.60. Ahead of these results, the company launched a review of its Performance & Care segment to sharpen its focus on specialty materials and advanced technologies across sectors such as aerospace, electronics, healthcare, energy, and advanced mobility. We’ll now consider how the Performance & Care segment...

Cmb.Tech NV ( EBR:CMBT ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...

In early May 2026, argenx SE received U.S. FDA approval to expand the VYVGART and VYVGART Hytrulo labels to treat all serotypes of adult generalized myasthenia gravis, supported by Phase 3 ADAPT SERON data showing rapid, clinically meaningful MG-ADL improvements and a safety profile consistent with prior use in anti-AChR-Ab positive patients. This expansion brings previously under-served groups, including anti-MuSK-Ab positive, anti-LRP4-Ab positive and triple seronegative patients, into...

Cmb.Tech (ENXTBR:CMBT) opened 2026 with a busy quarter, reporting Q1 revenue of US$807.3 million and basic EPS of US$1.27, while trailing twelve month revenue sat at US$2.2 billion with EPS of US$1.92. This gives investors a fresh read on both quarterly momentum and the rolling earnings base behind the current €14.58 share price. Over recent periods the company has seen revenue move from US$235.0 million in Q1 2025 and US$226.0 million in Q4 2024 to US$807.3 million in Q1 2026, with basic EPS...

Proximus PLC ( EBR:PROX ) came out with its quarterly results last week, and we wanted to see how the business is...

Why Anheuser-Busch InBev (ENXTBR:ABI) is back on radar Anheuser-Busch InBev (ENXTBR:ABI) has drawn fresh attention after a recent share move that leaves the stock up about 8.5% over the past month and 2.5% over the past 3 months. See our latest analysis for Anheuser-Busch InBev. For context, Anheuser-Busch InBev’s share price return is up 8.5% over the past month and 27.8% year to date, while the 1 year total shareholder return is 16.6%. This suggests momentum has been building recently. If...

Shareholders might have noticed that Nyxoah SA ( EBR:NYXH ) filed its first-quarter result this time last week. The...